Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01827111 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT01827111: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01827111 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01827111, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if the combination of ipilimumab and ABI-007 (abraxane) can help to control metastatic melanoma. The safety of this drug combination will also be studied. Ipilimumab is designed to increase the immune system's ability to fight cancer. Abraxane is designed to stop cancer cells from making new DNA (the genetic material of cells). This may stop the cancer cells from dividing into new cells.
Interventions
- DRUG Ipilimumab
- BEHAVIORAL Phone Call
- DRUG ABI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-04-25 |
| Est. Completion | 2020-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01827111
The ClinicalTrials.gov registry entry for NCT01827111 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ipilimumab is the first listed.
NCT01827111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01827111 about?
NCT01827111 is a clinical study titled "Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma". The goal of this clinical research study is to learn if the combination of ipilimumab and ABI-007 (abraxane) can help to control metastatic melanoma. The safety of this drug combination will also be studied. Ipilimumab is designed to increase the immune system's ability to fight cancer. Abraxane i...
What is the current status of trial NCT01827111?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2013-04-25. Estimated completion is 2020-09-21.
What interventions are being tested in trial NCT01827111?
The interventions under investigation include: Ipilimumab (DRUG), Phone Call (BEHAVIORAL), ABI-007 (DRUG).
Who is sponsoring clinical trial NCT01827111?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.